Entadfi
Product Images NDC 69681-125

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Entadfi (NDC 69681-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Veru Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Bottle Label (5 mg/5 mg)

Label for ENTADFI capsules by Veru Inc. Each capsule contains 5 mg finasteride and 5 mg tadalafil. The label includes the NDC 69681-125-30 and states a package count of 30 capsules. Dosage, storage instructions, and warnings for use by women and children are also indicated. The label features a 2D code and manufacturer contact details.*

FDA Label Image

Image Of Bottle Label (5 mg/5 mg)

Label for ENTADFI capsules 5 mg/5 mg (finasteride and tadalafil) by Veru Inc., presenting the product name, active ingredients, dosage strength, and a warning that it should not be used by women or children. The label includes recommended storage conditions, a QR code area, and product identification placeholders for GTIN, serial number, expiration date, and lot number, with a package count of 90 capsules.*

FDA Label Image

Image Of Chemical Structure Of Tadalafil (Cs1)

Chemical structure of the active ingredient in ENTADFI by Veru Inc. The diagram shows a complex molecular structure with indole and heterocyclic components, including a fused lactam ring and methoxy-substituted phenyl group.*

FDA Label Image

Image Of Chemical Structure Of Finasteride (Cs2)

Chemical structure diagram depicting the molecular structure of the active ingredient in ENTADFI, a drug by Veru Inc. The diagram shows the arrangement of atoms and bonds typical of a steroidal compound, highlighting functional groups and stereochemistry.*

FDA Label Image

Image Of Mean Maximal Change In Blood Pressure (tadalafil Minus Placebo, Point Estimate With 90% Ci) In Response To Sublingual Nitroglycerin At 2 (supine Only), 4, 8, 24, 48, 72, And 96 Hours After The Last Dose Of Tadalafil 20 mg Or Placebo (Fig1)

A set of four line graphs depicting blood pressure changes over time comparing tadalafil to placebo. The graphs show standing systolic and diastolic blood pressure, and supine systolic and diastolic blood pressure, with time in hours on the x-axis and blood pressure difference (mmHg) on the y-axis. Error bars represent variability at each time point.*

FDA Label Image

Image Of Doxazosin Study 1: Mean Change From Baseline In Systolic Blood Pressure (Fig2)

This image includes two line graphs showing the effects of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure (BP). The top graph plots standing systolic BP over 24 hours post-dose, and the bottom graph plots supine systolic BP over the same time frame. Both graphs display changes in BP in mmHg, with time in hours on the x-axis.*

FDA Label Image

Image Of Doxazosin Study 2 (part C): Mean Change From Time-matched Baseline In Systolic Blood Pressure (Fig3)

A line graph depicting systolic blood pressure (mmHg) over time after administration of tadalafil or placebo, combined with doxazosin. The x-axis shows time in hours up to 12 hours, and the y-axis shows systolic BP changes ranging from -20 to 20 mmHg. Four groups are plotted with different markers and line styles representing 20 mg tadalafil and 8 mg doxazosin at 08:00 and 20:00, as well as placebo with 8 mg doxazosin at the same times.*

FDA Label Image

Image Of Mean Total Ipss Changes By Visit In Bph Patients Taking Tadalafil Together With Finasteride (Fig4)

A line graph titled 'Weeks of Therapy' showing least-squares mean change from baseline over 26 weeks. Two treatment groups, Tadalafil/Finasteride and Placebo/Finasteride, are compared, with Tadalafil/Finasteride demonstrating a greater decrease. Statistical significance markers for p values less than 0.001 and 0.05 are indicated at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.